

Paulo M Hoff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11430157/publications.pdf>

Version: 2024-02-01

121
papers

9,289
citations

76196

40
h-index

39575

94
g-index

123
all docs

123
docs citations

123
times ranked

9811
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of Patients With Local Regrowth After Nonoperative Management of Rectal Cancer After Neoadjuvant Chemoradiotherapy. <i>Diseases of the Colon and Rectum</i> , 2022, 65, 333-339.	0.7	10
2	Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma. <i>Clinics</i> , 2021, 76, e2498.	0.6	4
3	Outcomes and Prognostic Factors in a Large Cohort of Hospitalized Cancer Patients With COVID-19. <i>JCO Global Oncology</i> , 2021, 7, 1084-1092.	0.8	14
4	Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy. <i>Clinics</i> , 2021, 76, e3146.	0.6	2
5	Real-world Data for High-risk Stage II Colorectal Cancer â€” The Role of Tumor Side in the Adjuvant Setting. <i>Clinical Colorectal Cancer</i> , 2020, 20, e100-e108.	1.0	1
6	Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer. <i>JAMA Network Open</i> , 2020, 3, e2020425.	2.8	11
7	Managing oncology clinical trials during COVID-19 pandemic. <i>Contemporary Clinical Trials Communications</i> , 2020, 19, 100637.	0.5	17
8	Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group. <i>Ecancermedalscience</i> , 2020, 14, 1048.	0.6	7
9	Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings. <i>Journal of Global Oncology</i> , 2019, 5, 1-6.	0.5	1
10	Evaluation of Continuous Tumor-Sizeâ€”Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2019, 2, e1911750.	2.8	6
11	Pharmacokinetic and exposureâ€”response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 539-550.	1.1	7
12	Young-age onset colorectal cancer in Brazil: Analysis of incidence, clinical features, and outcomes in a tertiary cancer center. <i>Current Problems in Cancer</i> , 2019, 43, 477-486.	1.0	12
13	Evaluation of 18F-FDG PET-CT as a prognostic marker in advanced biliary tract cancer. <i>Nuclear Medicine Communications</i> , 2018, 39, 252-259.	0.5	1
14	The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. <i>Journal of the National Cancer Institute</i> , 2018, 110, 888-894.	3.0	26
15	Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 470-475.	0.6	12
16	Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 1372-1384.	5.1	319
17	Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy. <i>Biomarker Research</i> , 2018, 6, 20.	2.8	7
18	Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 2564-2564.	0.8	1

#	ARTICLE	IF	CITATIONS
19	The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment. <i>Current Treatment Options in Oncology</i> , 2017, 18, 23.	1.3	165
20	Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair. <i>Clinical Colorectal Cancer</i> , 2017, 16, 228-239.	1.0	40
21	Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer. <i>JAMA Oncology</i> , 2017, 3, 767.	3.4	80
22	Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community. <i>Clinical Colorectal Cancer</i> , 2017, 16, 65-72.	1.0	6
23	Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group. <i>Ecancermedalscience</i> , 2017, 11, 716.	0.6	16
24	HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2558-2567.	0.8	98
25	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. <i>Journal of Clinical Oncology</i> , 2017, 35, 1929-1937.	0.8	37
26	Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care?. <i>Clinics</i> , 2017, 72, 588-594.	0.6	3
27	Replacing 5-fluorouracil by capecitabine in localised squamous cell carcinoma of the anal canal: systematic review and meta-analysis. <i>Ecancermedalscience</i> , 2016, 10, 699.	0.6	14
28	Review on TAS-102 development and its use for metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 104, 91-97.	2.0	6
29	Response to Paclitaxel in an Adult Patient with Advanced Kaposiform Hemangioendothelioma. <i>Case Reports in Oncology</i> , 2016, 9, 481-487.	0.3	6
30	Pathologic Complete Response in Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 255-263.	0.7	88
31	Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting. <i>Breast Cancer</i> , 2016, 23, 261-265.	1.3	2
32	Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. <i>Targeted Oncology</i> , 2016, 11, 383-400.	1.7	40
33	Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGIC-A Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 443-451.	0.8	490
34	Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 65.	3.4	134
35	Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. <i>Oncotarget</i> , 2015, 6, 34221-34227.	0.8	198
36	Are There Strategies to Integrate the Continuum of Care for Metastatic Colorectal Cancer When Resources Are Limited?. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 311-316.	1.0	0

#	ARTICLE	IF	CITATIONS
37	The Effects of Palliative Chemotherapy in Metastatic Colorectal Cancer Patients With an ECOG Performance Status of 3 and 4. <i>Clinical Colorectal Cancer</i> , 2015, 14, 52-57.	1.0	33
38	Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. <i>European Journal of Cancer</i> , 2015, 51, 18-26.	1.3	21
39	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. <i>Journal of Clinical Oncology</i> , 2015, 33, 22-28.	0.8	87
40	Adherence to colonoscopy recommendations for first-degree relatives of young patients diagnosed with colorectal cancer. <i>Clinics</i> , 2015, 70, 696-699.	0.6	7
41	Post-hoc analyses of overall survival (OS) and progression-free survival (PFS) in the TRIO-013/LOGiC trial of lapatinib (L) in combination with capecitabine plus oxaliplatin (CapeOx).. <i>Journal of Clinical Oncology</i> , 2015, 33, 133-133.	0.8	0
42	Randomized Phase III Trial Exploring the Use of Long-Acting Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1006-1011.	0.8	36
43	ERCC1 in Advanced Biliary Tract Cancer Patients Treated with Chemotherapy: Prognostic and Predictive Roles. <i>Journal of Gastrointestinal Cancer</i> , 2014, 45, 80-86.	0.6	4
44	Management of Colon Cancer and Liver Metastases: Is There a Role for Molecularly Targeted Agents?. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 133-139.	1.0	0
45	Primary prevention of colorectal cancer: Myth or reality?. <i>World Journal of Gastroenterology</i> , 2014, 20, 15060.	1.4	42
46	Cardiac Safety of (Neo)Adjuvant Trastuzumab in the Community Setting: A Single-Center Experience. <i>Breast Care</i> , 2014, 9, 255-260.	0.8	6
47	Percutaneous Transhepatic Biliary Drainage in Patients with Advanced Solid Malignancies: Prognostic Factors and Clinical Outcomes. <i>Journal of Gastrointestinal Cancer</i> , 2013, 44, 398-403.	0.6	27
48	Antiangiogenic Drugs for Colorectal Cancer: Exploring New Possibilities. <i>Clinical Colorectal Cancer</i> , 2013, 12, 1-7.	1.0	19
49	Do We Need another Antiangiogenesis Agent for Colorectal Cancer: are Bevacizumab and Aflibercept the Same?. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 317-325.	1.0	2
50	Modified FLOX as first-line chemotherapy for metastatic colorectal cancer patients in the public health system in Brazil: Effectiveness and cost-utility analysis. <i>Molecular and Clinical Oncology</i> , 2013, 1, 175-179.	0.4	12
51	Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors. <i>Rare Tumors</i> , 2013, 5, 121-125.	0.3	27
52	Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2012, 13, 1225-1233.	5.1	484
53	Role of angiogenesis in the pathogenesis of cancer. <i>Cancer Treatment Reviews</i> , 2012, 38, 825-833.	3.4	76
54	Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II). <i>Journal of Clinical Oncology</i> , 2012, 30, 3596-3603.	0.8	134

#	ARTICLE	IF	CITATIONS
55	Literature Review and Practical Aspects on the Management of Oxaliplatin-Associated Toxicity. <i>Clinical Colorectal Cancer</i> , 2012, 11, 93-100.	1.0	64
56	Squamous-cell carcinoma of the anal canal: Room for improvement with targeted therapy. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, 209-213.	0.7	4
57	A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2012, 48, 820-826.	1.3	16
58	Best Strategy in the Approach of Advanced Colorectal Cancer: Aggressive or Non-aggressive Chemotherapy?. <i>Current Colorectal Cancer Reports</i> , 2012, 8, 177-185.	1.0	0
59	Bevacizumab: overview of the literature. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 567-580.	1.1	79
60	Durable Complete Responses in Metastatic Colorectal Cancer Treated with Chemotherapy Alone. <i>Clinical Colorectal Cancer</i> , 2011, 10, 178-182.	1.0	47
61	Future Solutions for Patients with Metastatic Colorectal Cancer Positive for K-RAS Mutations. <i>Current Colorectal Cancer Reports</i> , 2011, 7, 275-280.	1.0	0
62	Case report: a rare cause of metabolic alkalosis. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, 164-166.	1.4	0
63	Integration of Anti-Vascular Endothelial Growth Factor Therapies With Cytotoxic Chemotherapy in the Treatment of Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 220-225.	1.0	4
64	Paclitaxel induced chronic fibrosing interstitial pneumonitis: a case report and review of the literature. <i>Oncology Reviews</i> , 2010, 4, 101-106.	0.8	2
65	Immune-mediated pancytopenia induced by oxaliplatin: a case report. <i>Transfusion</i> , 2010, 50, 1453-1459.	0.8	19
66	Review: Combination therapy in high-risk stage II or stage III colon cancer: current practice and future prospects. <i>Therapeutic Advances in Medical Oncology</i> , 2010, 2, 261-272.	1.4	34
67	Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. <i>Journal of Clinical Oncology</i> , 2010, 28, 453-459.	0.8	440
68	Oxaliplatin-Mediated Increase in Spleen Size As a Biomarker for the Development of Hepatic Sinusoidal Injury. <i>Journal of Clinical Oncology</i> , 2010, 28, 2549-2555.	0.8	188
69	Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer. <i>Oncology</i> , 2010, 79, 118-128.	0.9	21
70	Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics. <i>Journal of Clinical Oncology</i> , 2009, 27, 4103-4108.	0.8	224
71	Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. <i>Investigational New Drugs</i> , 2008, 26, 445-454.	1.2	74
72	Second-Line Chemotherapy Use in Metastatic Colon Cancer Varies by Disease Responsiveness. <i>Clinical Colorectal Cancer</i> , 2008, 7, 55-59.	1.0	6

#	ARTICLE	IF	CITATIONS
73	Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b. <i>Journal of Clinical Oncology</i> , 2008, 26, 1316-1323.	0.8	417
74	Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines. <i>Journal of Clinical Oncology</i> , 2008, 26, 2118-2123.	0.8	226
75	Adjuvant chemotherapy for stage II colon cancer. <i>Oncology</i> , 2008, 22, 260-70; discussion 270, 273, 275.	0.4	18
76	Targeted Therapy Trials: Approval Strategies, Target Validation, or Helping Patients?. <i>Journal of Clinical Oncology</i> , 2007, 25, 1639-1641.	0.8	14
77	Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 4557-4561.	0.8	406
78	The Role of EGFR Inhibition in Colorectal Cancer. , 2007, , 99-118.		1
79	Evidence of Clinical Activity for Cetuximab Combined with Irinotecan in a Patient with Refractory Anal Canal Squamous-Cell Carcinoma: Report of a Case. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 395-398.	0.7	41
80	Novel agents and targets for the therapy of advanced colon cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2007, 5, 365-6.	0.3	1
81	Clinical and Pathologic Predictors of Locoregional Recurrence, Distant Metastasis, and Overall Survival in Patients Treated With Chemoradiation and Mesorectal Excision for Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 219-224.	0.6	158
82	Small Cell Carcinomas of the Gastrointestinal Tract. , 2006, , 430-435.		2
83	Phase II study of capecitabine (Xeloda®) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 762-771.	0.4	110
84	Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: A matched-pair analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1378-1383.	0.4	81
85	Bevacizumab in Older Patients and Patients With Poorer Performance Status. <i>Seminars in Oncology</i> , 2006, 33, S19-S25.	0.8	6
86	Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer. <i>Cancer</i> , 2006, 106, 2241-2246.	2.0	9
87	Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. <i>Cancer</i> , 2006, 107, 1383-1390.	2.0	76
88	A Phase I Study of Escalating Doses of the Tyrosine Kinase Inhibitor Semaxanib (SU5416) in Combination with Irinotecan in Patients with Advanced Colorectal Carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2006, 36, 100-103.	0.6	32
89	Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality After Surgery for Hepatic Colorectal Metastases. <i>Journal of Clinical Oncology</i> , 2006, 24, 2065-2072.	0.8	1,198
90	Front-Line Therapy for Advanced Colorectal Cancer: Emphasis on Chemotherapy. <i>Seminars in Oncology</i> , 2005, 32, 40-42.	0.8	22

#	ARTICLE	IF	CITATIONS
91	Chemotherapy of metastatic colorectal cancer. Current Treatment Options in Gastroenterology, 2005, 8, 239-247.	0.3	9
92	Oxaliplatin-related neurotoxicity: is chelation the solution?. Nature Clinical Practice Oncology, 2004, 1, 78-79.	4.3	2
93	Targeting the Epidermal Growth Factor Receptor: An Important Incremental Step in the Battle Against Colorectal Cancer. Journal of Clinical Oncology, 2004, 22, 1177-1179.	0.8	47
94	Phase II Study of Capecitabine in Patients With Fluorouracil-Resistant Metastatic Colorectal Carcinoma. Journal of Clinical Oncology, 2004, 22, 2078-2083.	0.8	54
95	Future directions in the use of antiangiogenic agents in patients with colorectal cancer. Seminars in Oncology, 2004, 31, 17-21.	0.8	38
96	A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum. Investigational New Drugs, 2004, 22, 53-61.	1.2	12
97	Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer. Investigational New Drugs, 2004, 22, 307-313.	1.2	3
98	Progress in the development of novel treatments for colorectal cancer. Oncology, 2004, 18, 705-8.	0.4	5
99	Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century?. Oncology, 2004, 18, 736-41; discussion 742, 745-6.	0.4	1
100	The experience with oxaliplatin in the treatment of upper gastrointestinal carcinomas. Seminars in Oncology, 2003, 30, 54-61.	0.8	43
101	UFT and Oral Leucovorin as Radiation Sensitizers in Rectal and Other Gastrointestinal Malignancies. Cancer Investigation, 2003, 21, 624-629.	0.6	4
102	Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clinical Cancer Research, 2003, 9, 134-42.	3.2	76
103	Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2002, 20, 3605-3616.	0.8	305
104	Incidence and Severity of Hand-Foot Syndrome in Colorectal Cancer Patients Treated with Capecitabine: A Single-Institution Experience. Cancer Investigation, 2002, 20, 3-10.	0.6	93
105	Phase I and Pharmacokinetic Study of Exatecan Mesylate (DX-8951f): A Novel Camptothecin Analog. Journal of Clinical Oncology, 2001, 19, 1493-1500.	0.8	34
106	Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study. Journal of Clinical Oncology, 2001, 19, 2282-2292.	0.8	1,061
107	Improved Overall Survival Among Responders to Preoperative Chemoradiation for Locally Advanced Rectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 107-112.	0.6	246
108	Phase I bioequivalency study of MitoExtra and mitomycin C in patients with solid tumors. Cancer, 2001, 91, 815-821.	2.0	5

#	ARTICLE	IF	CITATIONS
109	Case Report: Hand-Foot Syndrome Induced by the Oral Fluoropyrimidine S-1. Japanese Journal of Clinical Oncology, 2001, 31, 172-174.	0.6	12
110	Thymidine Phosphorylase (TP) Activation: Convenience Through Innovation. Oncologist, 2001, 6, 1-2.	1.9	8
111	The Evolution of Fluoropyrimidine Therapy: From Intravenous to Oral. Oncologist, 2001, 6, 3-11.	1.9	40
112	Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. , 2000, 88, 2054-2060.		35
113	The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential. , 2000, 18, 331-342.		24
114	Novel oral chemotherapy agents. Current Oncology Reports, 2000, 2, 31-37.	1.8	8
115	Phase I Study of Preoperative Oral Uracil and Tegafur Plus Leucovorin and Radiation Therapy in Rectal Cancer. Journal of Clinical Oncology, 2000, 18, 3529-3534.	0.8	57
116	Progress in Colorectal Cancer Chemotherapy. Drugs and Aging, 2000, 17, 201-216.	1.3	11
117	Tegafur/Uracil + Calcium Folate in Colorectal Cancer. Drugs, 1999, 58, 77-83.	4.9	16
118	Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma. Investigational New Drugs, 1998, 16, 341-346.	1.2	16
119	Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. , 1998, 82, 965-969.		43
120	UFT Plus Oral Leucovorin: A New Oral Treatment for Colorectal Cancer. Oncologist, 1998, 3, 155-164.	1.9	27
121	Paclitaxel-Induced Pancreatitis: A Case Report. Journal of the National Cancer Institute, 1997, 89, 91-93.	3.0	16